Luminex Corporation Announces the Release of xPONENT® 3.1 Software

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced the commercial release of xPONENT® 3.1 data acquisition software. Launched for use on Luminex 100 and Luminex 200 systems, xPONENT 3.1 includes more than 65 new features designed to benefit scientists and laboratory professionals across research and clinical diagnostic markets in simplifying laboratory workflow and increasing productivity. Luminex simultaneously announced that it has added xPONENT 3.1 to its FDA-cleared Luminex 100 and 200 systems for use in clinical diagnostic applications.

“xPONENT 3.1 is an innovative and exciting software upgrade for Luminex’s partners and customers, as it provides a range of new tools to help scientists work more efficiently and effectively,” said Patrick Balthrop, President and Chief Executive Officer of Luminex. “Furthermore, adding the new software to our FDA-cleared multiplexing system allows our partners and customers in the diagnostics field to upgrade their laboratories.”

xPONENT 3.1 was developed with direct feedback from users across a range of research and clinical diagnostic disciplines. The software is being released together with repackaged system reagents and a new Automated Maintenance Plate (AMP). These components combine to enable the automation of daily system maintenance operations and to increase walk-away time.

New features and enhancements of the xPONENT 3.1 software product line include an intuitive navigation structure, touch-screen capability, intra-well normalization function, advanced data-analysis tools and an enhanced database and underlying data management architecture.

For laboratories working under the FDA’s 21 CFR part 11 regulations, xPONENT software offers multilevel user management, full audit trail electronic records and electronic signatures. The software can be included in integrated systems interfaced with Laboratory Information Systems (LIS/LIMS) and front-end automation platforms. It has been designed to support both carboxylated and magnetic bead applications.

xPONENT 3.1 will be sold on new Luminex systems and will be available as an upgrade to the more than 5,800 existing Luminex 100 and 200 systems in the marketplace worldwide.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company’s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.